August 31, 2012
| Drug Name | Active Ingredient | Dosage Form/Route | Sponsor | Submission Type | 
|---|---|---|---|---|
| Azelastine Hydrochloride | azelastine hydrochloride | Spray, Metered; Nasal | Apotex Inc | Approval | 
| Exelon | rivastigmine | Film, Extended Release; Transdermal | Novartis | Efficacy Supplement with Clinical Data to Support | 
| Felbatol | felbamate | Suspension; Oral | Meda Pharms | Labeling Revision | 
| Felbatol | felbamate | Tablet; Oral | Meda Pharms | Labeling Revision | 
| Mirapex | pramipexole dihydrochloride | Tablet; Oral | Boehringer Ingelheim | Efficacy Supplement with Clinical Data to Support | 
| Mirapex Er | pramipexole dihydrochloride | Tablet, Extended Release; Oral | Boehringer Ingelheim | Efficacy Supplement with Clinical Data to Support | 
| Vinorelbine | vinorelbine | Injectable; Injection | Onco Therapies Ltd | Approval | 
| Xtandi | enzalutamide | Capsule; Oral | Medivation | Approval | 
Comments
Post a Comment